The dopamine D1/D2 agonist apomorphine (0.63 mg/kg) disrupted prepulse inhibition (PPI) of acoustic startle in rats, a model of sensorimotor gating deficits observed in schizophrenia. All current antipsychotics, which antagonize D 2 receptors, prevent this apomorphine-induced deficit. A novel class of antipsychotics possesses, in addition to D 2 antagonist property, various levels of 5-HT 1A agonist activity. Considering that the latter itself produces PPI deficits, it appeared necessary to assess the potential of this novel class of antipsychotics to reverse apomorphine-PPI deficits. Potent D 2 antagonists, like haloperidol (0.63-2.5 mg/kg), risperidone (0.63-10 mg/kg), and olanzapine (0.63-40 mg/kg) prevented apomorphine PPI disruption. The atypical antipsychotics, clozapine (40 mg/kg), nemonapride (0.01-2.5 mg/kg), ziprasidone (10 mg/kg), and aripiprazole (0.01 and 10 mg/kg), which all exhibit 5-HT 1A agonist properties, reversed PPI deficits at some doses only, whereas the anti-dyskinetic agent sarizotan (0.16-10 mg/kg), an efficacious 5-HT 1A agonist, did not. New generation antipsychotics with marked 5-HT 1A agonist properties, such as SLV313 and SSR181507 (0.0025-10 mg/kg and 0.16-10 mg/kg, respectively) did not reverse these deficits whereas bifeprunox (0.04-2.5 mg/kg) did. To reveal the contribution of 5-HT 1A agonist properties in the lack of effects of SLV313 and SSR181507, we pretreated rats with the 5-HT 1A antagonist WAY100635 (0.63 mg/kg). Under these conditions, significant reversal of PPI deficit was observed, indicating that D 2 antagonist properties of SLV313 and SSR181507 are now sufficient to overcome the disruptive effects of apomorphine. To summarize, antipsychotics possessing agonist efficacy at 5-HT 1A receptors exhibit diverse profiles against apomorphine-induced PPI deficits, depending on the balance between D 2 and 5-HT 1A activities, suggesting that they may display distinct activity on some aspects of gating deficits in schizophrenic patients.
INTRODUCTION
Several neuropsychiatric disorders, such as schizophrenia, are associated with deficits in sensorimotor gating, and the prepulse inhibition (PPI) model of the acoustic startle reflex was developed in rodents to mimic these deficits (Geyer and Braff, 1987; Geyer, 1990, 2001) . PPI is defined as the attenuation of the response to a startling stimulus (pulse), when such a stimulus is briefly preceded by a stimulus of subthreshold intensity (prepulse). PPI can be disrupted by acting on developmental and environmental factors such as isolation rearing of rats (Geyer et al, 1993; Varty et al, 1999) , early maternal or nutritional deprivation (Ellenbroek et al, 1998) , and neonatal lesions of neuronal circuitry linking the limbic structures and basal ganglia (Lipska et al, 1995) . However, the pharmacological disruption approach, for reasons of ease of implementation, is more commonly used. Among the three main pharmacological models of disruption of PPI in rats, that is, those induced by dopamine (DA) receptor agonists, 5-HT 2A receptor agonists, and NMDA/glutamate receptor antagonists, the DA receptor agonist-induced PPI deficit model appears to be the best-validated for the identification of antipsychotics with DA D 2 receptor blocking properties. Indeed, PPI can be disrupted by either direct DA receptor agonists, such as apomorphine, or indirect DA agonists that facilitate dopaminergic transmission, such as d-amphetamine, and these effects can be prevented by DA D 2 (and/or D 1 ) receptor antagonists (Swerdlow et al, 1986 (Swerdlow et al, , 1994 Mansbach et al, 1988) . Hence, antipsychotics that have appreciable affinity for DA D 2 receptors such as haloperidol, reliably prevent apomorphine-induced deficits in rats (Mansbach et al, 1988; Geyer et al, 2001; Ralph and Caine, 2005) .
All current antipsychotics have more or less marked DA D 2 receptor antagonists properties, thought to be responsible for their efficacy, at least against positive symptoms (Kapur and Remington, 2001; Wadenberg et al, 2000b) . Another major monoaminergic system, the serotonergic system, has also been implicated in various aspects of the neurobiology of schizophrenia. Two subtypes of serotonin receptors, the 5-HT 2 and the 5-HT 1A , have been the objects of great interest. As a matter of fact, most atypical antipsychotics are DA D 2 and 5-HT 2 receptors blockers, and it has been proposed that antagonist activity at 5-HT 2 receptors prevents the deleterious effects of DA D 2 receptor blockade, that is, extrapyramidal signs (EPS) (Kapur, 1996; Remington and Kapur, 1999) . Besides, there is ample preclinical evidence that activation of 5-HT 1A receptors should also prove beneficial in schizophrenia (Millan, 2000; Bantick et al, 2001; Ichikawa et al, 2001) . Hence, it has been repeatedly shown that 5-HT 1A receptor agonists prevent catalepsy (an animal model of EPS) produced by blockade of DA D 2 receptors (Wadenberg and Ahlenius, 1991; Wadenberg et al, 1994; Neal-Beliveau et al, 1993; Prinssen et al, 1998 Prinssen et al, , 1999 Depoortere et al, 2003; Kleven et al, 2005) . Consistent with this idea, clinical studies have reported that buspirone and tandospirone, two partial agonists at 5-HT 1A receptors, reduce the incidence of EPS in schizophrenic patients treated with haloperidol (Sumiyoshi et al, 2001a, b) . Furthermore, these studies have also shown that buspirone and tandospirone substantially ameliorate cognitive performance of patients. At the pre-clinical level, microdialysis experiments have shown that 5-HT 1A receptor activation increases DA release in prefrontal cortex (Rollema et al, 1997 (Rollema et al, , 2000 Millan et al, 1998; Sprouse et al, 1999; Ichikawa and Meltzer, 2000) . In the light of the proposed deficiency in dopaminergic neurotransmission in this brain area in schizophrenic patients, this 5-HT 1A receptor-mediated augmentation of cortical DA tone should help in alleviating negative and cognitive deficits of schizophrenia. In addition, 5-HT 1A receptor expression is increased in the dorsolateral prefrontal, temporal, and orbital frontal cortices of autopsied brains from chronic schizophrenics (Hashimoto et al, 1991; Simpson et al, 1996; Burnet et al, 1997) . Further, PET studies have revealed an increase in cortical 5-HT 1A receptor binding in schizophrenia (Kasper et al, 2002) .
These considerations have led to the development of compounds with preferential DA D 2 receptor antagonist or partial agonist, and 5-HT 1A agonist activities, such as bifeprunox (Feenstra et al, 2001; Wolf, 2003) , SSR181507 (Claustre et al, 2003; Depoortere et al, 2003; Boulay et al, 2004) , SLV313 McCreary et al, 2002) , and sarizotan (that has been re-oriented towards an antidyskinetic indication: Bibbiani et al, 2001; Rabiner et al, 2002; Bartoszyk et al, 2004) .
However, it has been reported that activation of 5-HT 1A receptors by agonists such as 8-OH-DPAT and buspirone, disrupts PPI of the acoustic startle response in rodents (Nanry and Tilson, 1989; Rigdon and Weatherspoon, 1992; Geyer, 1994, 1995a; Sipos et al, 2000) . Notwithstanding the numerous reports of deleterious effects of 5-HT 1A receptor agonists on PPI, activity of mixed DA D 2 receptor antagonist/partial agonist and 5-HT 1A agonist on models of sensorimotor gating deficits have not been characterized. We therefore examined the ability of such drugs to prevent apomorphine-induced PPI deficits, since the influence of their 5-HT 1A agonist properties on sensorimotor gating is unknown. The present study had two objectives: First, to compare the effects of these new compounds with those of older antipsychotic agents (haloperidol, clozapine, ziprasidone, risperidone, olanzapine, aripiprazole, and nemonapride) acting by a variety of mechanisms in addition to/instead of 5-HT 1A receptor activation. For the purpose of internal validation, we included the selective 5-HT 1A receptor agonist, F13714 (Koek et al, 2001 ) to verify, under our experimental conditions, the disruptive influence of 5-HT 1A receptor activation. Second, to verify that effects of compounds with preferential 5-HT 1A receptor agonist properties were specifically mediated through this receptor; to that end, interaction studies with the specific 5-HT 1A receptor antagonist WAY100635 were undertaken whenever appropriate.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (ICO: OFA SD, Iffa Credo, Les Oncins, France), weighing 180720 g upon arrival were group-housed (n ¼ 5/cage) in an environmentally controlled room (temperature 21711C and relative humidity 5575%) on a 12 h : 12 h light : dark cycle (lights on at 0700), in stainless steel cages with grid flooring (internal dimensions: 26 Â 42 Â 18 cm; W Â L Â H). Animals were held in quarantine for 4-8 days, with free access to standard laboratory food (A04, Scientific Animal Food and Engineering, Epinay sur Orge, France) and filtered water (0.22 mm pores; in bottles). A 5-day acclimatization period was allowed before animals were used in experiments. Twenty-four hours before testing, the animals were individually housed in an environmentally controlled test room in plastic hanging cages with a grid floor (internal dimensions: 11 Â 31 Â 18 cm; W Â L Â H), where they had free access to water, but not food. Animals were handled and cared for in accordance with the 'Guide and Care and Use of Laboratory Animals (National Institutes of Health) and the European Directive 86/609, and was carried out in compliance with French regulations and the local ethical committee guidelines for animal research.
Apparatus
Startle chambers (SR LAB, San Diego Instruments, San Diego, CA) were used. Each chamber consisted of a transparent acrylic cylinder (inside diameter: 8.8 cm; inside length: 18.4 cm), resting on a Plexiglas base in a soundattenuated ventilated enclosure illuminated by a 15 W lamp. Pulses and pre-pulses (white noise bursts) were presented via a loudspeaker mounted 28 cm above the animal. Startle reflexes within the cylinder were detected by a piezoelectric accelerometer attached to the base. Response sensitivities were calibrated using a standard calibrator tube (San Diego Instruments), and were adjusted to 150 units. Sound levels were calibrated (71 dB) using the A scale of a sound level meter (Radio Shack, Tandy Corp., Fort Worth, TX). All events were controlled and recorded on a PC using the San Diego Instruments Startle software.
Procedure
Pre-test and test sessions. Animals, which were used only once, were pre-tested in startle chambers 1 h 45 min before the pharmacological challenge (test) session. This pre-test session that lasted 13 min, was used to habituate rats to the procedure. Three different trial types were presented against a continuous 70 dB background noise: no pulse (NP), 118 dB pulse (pulse alone; PA), and 78 dB prepulse (pp) followed by a 118 dB pulse (prepulse-pulse; ppP). The PA and P duration was 40 ms, the pp duration 20 ms, and the interval between the end of the pp and the onset of the PA or P 80 ms. Sessions started with a 5-min adaptation period after which the animals were exposed to 10 PA (included to induce habituation to startle, such that habituation during the following PPI assessment would be minimized: these trials were not used for data analysis). These 10 PA trials were followed by 10 PA, 10 ppP, and 3 NP trials presented in a pseudo-random order. The interval between trials was variable but with a median of 15 s. The startle response was defined as the average amplitude measured during 100 consecutive samples of 1 ms, which were recorded from the onset of the pulse by means of a 12-bit AD acquisition card (range: 0-4095 arbitrary units). Rats were returned to their home cages at the end of the pre-test session.
Test sessions were in all respects similar to the pre-test sessions (vide supra). Rats that showed any one of these four criteria at least once during either the pre-test or test session were not retained for data analysis: (i) an amplitude of the startle reflex following presentation of the PA less than 10 arbitrary units, or (ii) more than four amplitudes for PA equal to 4095 (ceiling value of the 12-bits AD acquisition card) for the PA condition or for the ppP condition, or (iii) a (PA-NP) amplitude/PA amplitude o80% or (iv) a pp amplitude4PA amplitude (this last elimination criterion was used only for the pre-test session).
Pharmacological treatments. At the end of the pre-test session, animals were treated as follows: for the dose-effect study of apomorphine and F13714, animals were injected s.c. 60 min before the beginning of the test session with vehicle, and 45 min later with apomorphine or F13714. For the reversion of the apomorphine-induced PPI deficits with antipsychotics, animals were injected 60 min before with the test compound or its vehicle, and 45 min later with apomorphine. For the interaction of the 5-HT 1A antagonist and SLV313 or SSR181507, WAY100635 or its vehicle was injected s.c. 75 min before the beginning of the test session, followed by the injection protocol described right above. The dose of apomorphine used in double and triple treatments was 0.63 mg/kg. After each injection, the animals were put back in their home cages. Following is a schematic of the injection protocol: 
Data Analysis
For each test session, the median of the amplitude of the startle responses for the last 10 PA trials and for the 10 ppP was calculated. The percentage PPI was calculated as follows:
ðmedian PA amplitude À median ppP amplitudeÞÂ100 ðmedian PA amplitudeÞ Data (percentage PPI) were analyzed with an one-way ANOVA with the treatment as the between-subjects factor, followed by a Dunnett's post hoc test for comparison with the saline/saline group (for the apomorphine and F13714 dose-response study) or the saline/apomorphine group (for the apomorphine/antipsychotics interaction experiments).
For the experiments on the interaction between WAY100635 and SLV313 or SSR181507, a non-parametric (KruskalWallis) test was used (due to heterogeneity of variance) to compare the saline/test compound/apomorphine groups to the WAY100635/test compound/apomorphine groups. It was followed by a Dunn's post hoc test for comparing pretreatment with saline or WAY100635 for selected doses of test compounds.
Drugs
Haloperidol, clozapine, and apomorphine HCl were obtained commercially (Sigma RBI, St Quentin Fallavier, France). Ziprasidone HCl, aripiprazole, bifeprunox mesylate (DU-127090; N-[4-[(3-chloro- 
were synthesized by J-L Maurel at the Centre de Recherche Pierre Fabre (Castres, France). SLV313 HCl (piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl) was generously donated by Solvay Pharmaceuticals (Weesp, The Netherlands). SSR181507 (0.16-10 mg/kg), F13714 (0.0025-10 mg/kg), apomorphine (0.04-2.5 mg/kg), and WAY100635 (0.63 mg/kg) were prepared in distilled water and administered s.c., whereas aripiprazole (0.01-10 mg/kg), bifeprunox (0.01-40 mg/kg), sarizotan (0.16-10 mg/kg), and ziprasidone (0.04-10 mg/kg) were prepared as a suspension in aqueous Tween 80 (two drops/10 ml distilled water) and administered i.p. SLV313 (0.0025-10 mg/kg), nemonapride (0.00063-2.5 mg/kg), olanzapine (0.16-40 mg/kg), risperidone (0.04-10 mg/kg), clozapine (2.5-40 mg/kg), and haloperidol (0.01-2.5 mg/kg) were prepared in distilled water with a drop of lactic acid, after which the pH was adjusted to 5-7 with a 1 N solution of sodium hydroxide, and were injected s.c. (except clozapine: i.p.). An injection volume of 10 ml/kg was used throughout and doses refer to the weight of the free base. For each compound, doses were administered in an unsystematic order. Rats were injected 60 min before testing with vehicle, followed 45 min after by apomorphine or F13714 or vehicle. The percentage PPI was calculated as: [(median PA amplitude -median ppP amplitude) Â 100]/(median PA amplitude). Symbols are means7SEM. Data were analyzed using one-way ANOVA's followed by Dunnett's post hoc tests. **po0.01, compared with the vehicle/vehicle control group. N ¼ 7-9 rats per dose. For SLV313, although there was a significant global effect of the ANOVA (F(7,213) ¼ 2.38, p ¼ 0.02: Figure 4c) , post hoc Dunnett's test did not detect any dose that differed significantly from control. In contrast, bifeprunox (0.04-2.5 mg/kg: Figure 4d ) prevented PPI deficits (F(7,213) ¼ 6.83, po0.0001, Dunnett's post hoc test: for 0.04 mg/kg: po0.01, for 0.16 mg/kg: po0.05, for 0.63 mg/kg: po0.01, for 2.5 mg/kg: po0.01). For the higher doses of 10 and 40 mg/kg, bifeprunox did not significantly reverse the effects of apomorphine (p40.05).
RESULTS
Masking by Pretreatment with WAY100635 of the 5-HT 1A Agonist Properties of SLV313 and SSR181507: Effects on Apomorphine-Induced PPI Deficits , vehicle or test compound, followed by apomorphine (0.63 mg/kg, s.c.), 75 min, 60 min and 15 min, respectively, before testing. Data were analyzed using nonparametric Kruskal-Wallis tests followed by a Dunn's post-hoc tests. *po0.05 and **po0.01, comparing the WAY100635 pretreated with the saline-pretreated group, at the considered dose of the test compound. See legend of Figure 1 for details. N ¼ 9 rats per dose.
Note: effects of compounds on PPI and on pulse alone (PA) amplitude did not appear to be correlated. Table 1 contains a non-exhaustive list of a series of drug treatments, with their effects on PA amplitude and on %PPI. It can be seen that some treatments increased the PA amplitude but decreased the %PPI (first line), while others did not modify the PA amplitude but increased the %PPI (second line), diminished the PA amplitude but augmented (third line) or left intact (fourth line) the %PPI, and finally increased both the PA amplitude and the %PPI (fifth line).
DISCUSSION
The PPI paradigm employed in the present study is widely used for characterizing antipsychotic drugs, and has been claimed to possess face validity, since apomorphineinduced startle gating deficits in rats mimic the abnormalities of gating that are thought to underlie sensory flooding and cognitive fragmentation present in schizophrenic patients (McGhie and Chapman, 1961; Braff et al, 2001) . These deficits can be reversed by 'typical' high-potency DA D 2 receptor antagonists and 'atypical' antipsychotics with low activity at 5-HT 1A receptors (Swerdlow et al, 1986 (Swerdlow et al, , 1994 Mansbach et al, 1988; Geyer et al, 2001) . However, activation of 5-HT receptor subtypes, such as 5-HT 2A and 5-HT 1A interferes with sensorimotor gating (Mansbach et al, 1988; Nanry and Tilson, 1989; Rigdon and Weatherspoon, 1992; Sipes and Geyer, 1994 , 1995a , b, 1997 Sipos et al, 2000; Wadenberg et al, 2000a; Roth et al, 2004) . As such, the exploration of activity of drugs acting preferentially at DA D 2 and 5-HT 1A receptors (currently under development as antipsychotics) in the apomorphine-PPI model was warranted. The present data show that a wide diversity of responses is observed among these novel compounds (including SSR181507, bifeprunox, SLV313, and sarizotan), which distinguishes them from existing classes of conventional and 'atypical' antipsychotics.
Antipsychotics with Marked DA D 2 Antagonist But Devoid of 5-HT 1A Agonism Properties Over a broad range of doses (0.63-10 mg/kg or 40 mg/kg), haloperidol, risperidone, and olanzapine prevented the PPI disruptive effects of apomorphine, confirming previous data (Mansbach et al, 1988; Geyer et al, 1990; Schwarzkopf et al, 1993; Rasmussen et al, 1997) . These antipsychotics behave as DA D 2 receptor antagonists, with low or no affinity at 5-HT 1A receptors (Newman-Tancredi et al, 1998; Leysen, 2005) . Indeed, the ratios of Ki (rKi) at 5-HT 1A vs DA D 2 receptors were 275, 468, and 1738, for olanzapine, risperidone, and haloperidol, respectively (NewmanTancredi et al, 2005) . Considering that disruption of PPI by the DA receptor agonist apomorphine has been demonstrated to result primarily by activation of DA D 2 receptors in rats (Swerdlow et al, 1986; Mansbach et al, 1988; Geyer et al, 2001) , the reversion observed with these three compounds is consistent with their receptorial profile.
'Atypical' Antipsychotics Possessing, Among Other Properties, 5-HT 1A Agonist Activities
Clozapine at the highest dose tested (40 mg/kg) reversed the reduction of PPI induced by apomorphine, confirming previous results for this 'atypical' antipsychotic (Swerdlow et al, 1991 (Swerdlow et al, , 1998 Mansbach et al, 1998) . This reversing effect can be explained based on a low efficacy at 5-HT 1A receptors (12% that of ( + )8-OH-DPAT in an assay of [ 35 S]GTPgS stimulation in rat hippocampal membrane: Newman-Tancredi et al, 2005) combined with a rather low pKi (3.3) . The low potency of clozapine is consistent with its very moderate affinity for the DA D 2 receptor (pKi: 6.31: Newman-Tancredi et al, 2005) . In contrast, nemonapride almost completely prevented PPI deficits over a dose-range of 0.01-2.5 mg/kg. Here again, the rKi was high (37), indicating that over this dose-range, DA D 2 receptor blockade largely predominates over the agonist activity at 5-HT 1A receptors. Its rather potent efficacy to activate 5-HT 1A receptors (39% that of ( + )8-OH-DPAT in an assay of [
35 S]GTPgS stimulation in rat hippocampal membrane: Newman-Tancredi et al, 2005) might explain why the reversing effect is not full at higher doses. Indeed, in a catalepsy test, it was observed that nemonapride produced catalepsy at lower doses (0.04-0.63 mg/kg s.c.) but not at higher doses (from 2.5 to 40 mg/kg s.c.), indicating that the 5-HT 1A agonist properties of nemonapride appear at doses approximately 16-64 fold higher than those blocking DA D 2 receptors (Prinssen et al, 1998) .
The 5-HT 1A receptor partial agonist/DA D 2 receptor antagonist ziprasidone, and the DA D 2 receptor and 5-HT 1A receptor partial agonist aripiprazole, reversed apomorphine-induced PPI deficits at some doses only (10 mg/kg, (Cosi et al, in press ). As a consequence, the partial agonist activity at DA D 2 receptors at low doses is relayed by the 5-HT 1A receptor partial agonist properties at higher doses, resulting in a lack of clear-cut reversing effect. In addition, in both rats and humans, a major metabolite of aripiprazole is a pure DA D 2 receptor antagonist (Lawler et al, 1999) , which adds a further dimension to the complexity of pharmacological interaction between apomorphine and aripiprazole in this test.
Influence of 5-HT 1A Receptor Agonism on the Ability of Novel Antipsychotics Selectively Targeting DA D 2 and 5-HT 1A Receptors to Reverse Apomorphine-Induced PPI Deficits
Neither SSR181507, SLV313 nor sarizotan reversed apomorphine-induced PPI deficits. All three compounds are characterized by their strong affinity for and fairly high efficacy at 5-HT 1A receptors . These data are consistent with the disruptive influence of the selective 5-HT 1A agonist, F13714 (Figure 1b) , and of the prototypic 5-HT 1A agonist, 8-OH-DPAT, as well as the partial 5-HT 1A agonists, buspirone, gepirone, and ipsapirone (Rigdon and Weatherspoon, 1992; Sipes and Geyer, 1995a; Sipos et al, 2000) . Among a whole series of compounds tested , sarizotan exhibited the highest efficacy at 5-HT 1A receptors (100% that of ( + )8-OH-DPAT), and possessed a low rKi (0.3). Furthermore, sarizotan behaved as a partial DA D2 receptor agonist Kuzhikandathil et al, 2004) . These observations indicate that the 5HT 1A receptor agonist properties of sarizotan are predominant: this most likely explains the lack of activity of this compound against apomorphine-induced PPI disruption, and might also be the reason why it was originally developed as an antipsychotic, but has been more recently re-oriented towards an anti-dyskinetic indication (Bibbiani et al, 2001 ). SSR181507 exhibited a moderate efficacy at 5-HT 1A receptors (39% that of ( + )8-OH-DPAT) with a rKi of 0.8, and also behaved as a partial DA D 2 receptor agonist (18% that of apomorphine, Cosi et al, in press ). Here again, it can be considered that the compound preferentially activates 5-HT 1A receptors, hence its lack of activity against apomorphine-induced PPI impairment. The case for SLV313 is slightly different: despite the fact that it had even more moderate efficacy at 5-HT 1A receptors (28% that of ( + )8-OH-DPAT), its rKi was also close to unity (0.9: Newman-Tancredi et al, 2005) but it behaved as a DA D 2 receptor antagonist McCreary et al, 2002; Cosi et al, in press ). Nonetheless, it seems that overall, its 5-HT 1A receptor agonist activity predominates. It should be noted, however, that in the only other study (in an abstract form) published on SLV313, it was reported that the compound could attenuate effect of PPI disruption at doses less than 0.1 mg/kg (McCreary et al, 2002) . The reasons for this discrepancy between this study and ours are not clear at the moment. Administration of the 5-HT 1A receptor antagonist WAY-100635 revealed the ability of SSR181507 and SLV313 to prevent apomorphine-induced PPI deficits. This provides a cogent demonstration implicating the 5-HT 1A receptor agonist activity of these compounds in their lack of efficacy for reversal of this type of disruption.
Surprisingly, bifeprunox potently prevented apomorphine-induced gating deficits at doses from 0.04 to 2.5 mg/ kg, with a loss of activity at 10 and 40 mg/kg. One possible explanation is that bifeprunox, although having a quite substantial efficacy at 5-HT 1A receptors (54% that of ( + )8-OH-DPAT), has higher affinity for D 2 than for 5-HT 1A receptors (rKi of 44). It thus appears that the partial agonist activity at DA D 2 receptors (27% that of apomorphine, Cosi et al, in press) predominates over this dose-range, and reverses the deficit produced by the full D 2 receptor agonist apomorphine whereas at higher doses (10 and 40 mg/kg), the 5-HT 1A agonist activity exerts its deleterious effects on PPI.
SUMMARY AND CONCLUSIONS
Although several novel antipsychotics share the capacity to interact at both 5-HT 1A and DA D 2 receptors, their ability to reverse apomorphine-induced PPI deficits is highly diverse. In fact, this variety of profiles could be related to their diverging affinities and efficacies at 5-HT 1A and DA D 2 receptors, as has been characterized in detail in cellular models of receptor interaction (Newman-Tancredi et al, 2005, Cosi et al, in press ). Thus, the present data suggest that in this apomorphine-induced gating deficits model, a narrow window of efficacy exists between DA D 2 receptor blockade and serotonin 5-HT 1A receptor activation. While the latter property is considered to be desirable for attenuating negative, cognitive, and affective symptoms of schizophrenia, as well as neuroleptic-induced EPS (Millan, 2000; Bantick et al, 2001; Kleven et al, 2005) , it appears that too pronounced an activation of 5-HT 1A receptors impairs the ability of compounds, such as SLV313 and SSR181507 to reverse apomorphine-induced PPI deficits. Taken together, these data indicate that 5-HT 1A activation can alter the antipsychotic-like effects of DA D 2 receptor antagonists in this model of positive symptoms of schizophrenia. However, this does not hold true for at least one other model predictive of antipsychotic activity, such as the active (two-way) avoidance task: in mice, the coadministration of the 5-HT 1A antagonist SL88.0338 did not modify the activity of SSR181507 in this test (Depoortere et al, 2003) . In addition, data obtained in the same test but in rats, suggest that the potency of DA D 2 receptor antagonists (such as raclopride and haloperidol) is even enhanced by addition of a compound with 5-HT 1A agonist properties such as 8-OH-DPAT (Prinssen et al, 1996) .
Taken together, these considerations indicate complex interactions in the balance of DA D 2 and 5-HT 1A activities that could profoundly influence the pharmacological and therapeutic profiles of new generation ligands targeting these receptors.
